Side-by-side comparison of AI visibility scores, market position, and capabilities
Denver CO AI platform (NYSE: PLTR) $2.87B FY2024 revenue (+29%); US Commercial +54%, AIP boot camps, S&P 500 addition Sept 2024, competing with Microsoft Azure AI and C3.ai.
Palantir Technologies Inc. is a Denver, Colorado-based artificial intelligence and data analytics platform company — publicly traded on the New York Stock Exchange (NYSE: PLTR) as an S&P 500 Technology component (added September 2024) — building software platforms for government intelligence and defense analytics (Gotham), commercial enterprise AI operations (Foundry), and the Palantir Artificial Intelligence Platform (AIP) for enterprise AI deployment through approximately 3,800 employees. In fiscal year 2024, Palantir reported revenues of $2.87 billion (+29% year-over-year), with US Commercial revenue reaching $702 million (+54%), US Government revenue $912 million (+40%), and International revenue $1.26 billion (+13%) — demonstrating the acceleration of AI-driven commercial adoption beyond Palantir's defense intelligence origins. CEO Alex Karp's strategy of positioning Palantir as the enterprise AI operating system — the platform on which organizations deploy, govern, and scale AI agents and large language models in production — drove AIP adoption through Palantir's "boot camp" methodology: a 5-day intensive workshop where potential customers deploy AIP on their own data to demonstrate specific use cases before any contract commitment, reducing enterprise AI proof-of-concept cycle time from months to days. The S&P 500 inclusion in September 2024 triggered index fund purchases and elevated Palantir's institutional ownership profile, with the stock price rising from approximately $17 to over $70 during 2024 as AI platform enthusiasm drove valuation expansion to 50-80x forward revenue multiples.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.